Roosevelt Institute | Cornell University

The Plight of the Drug Industry

By Seth Kim Published February 28, 2019

Pharmaceutical companies are moving towards a business model of mostly in-licensing deals, which has been increasing profits at the cost of decreasing innovation. In order to increase the rate of novel drug development, the FDA should reconsider its policies to be more accomodating of complex technologies and methodologies.